Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial

Orally administered cannabidiol does not produce false‐positive tests for Δ 9 ‐tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000

(2021) Danielle McCartney et al.   Drug Testing and Analysis

Medicinal cannabis and driving: the intersection of health and road safety policy

(2021) Daniel Perkins et al.   INTERNATIONAL JOURNAL OF DRUG POLICY

Abrupt withdrawal of cannabidiol (CBD): A randomized trial

(2020) Lesley Taylor et al.   EPILEPSY & BEHAVIOR

Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis

(2020) Nicolas J. Schlienz et al.   DRUG AND ALCOHOL DEPENDENCE

Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users

(2020) Tory R. Spindle et al.   DRUG AND ALCOHOL DEPENDENCE

The effect of cannabidiol on simulated car driving performance: A randomised, double‐blind, placebo‐controlled, crossover, dose‐ranging clinical trial protocol

(2020) Danielle McCartney et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Robustness of linear mixed‐effects models to violations of distributional assumptions

(2020) Holger Schielzeth et al.   Methods in Ecology and Evolution

A validated method for the simultaneous quantification of CBD, THC, and their metabolites in human plasma, and application to plasma samples from an oral CBD open label trial

(2020) Richard C. Kevin et al.   Drug Testing and Analysis

Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance

(2020) Thomas R. Arkell et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition

(2019) Thomas R. Arkell et al.   PSYCHOPHARMACOLOGY

A systematic review of cannabidiol dosing in clinical populations

(2019) S.A. Millar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy

(2019) Angela K. Birnbaum et al.   EPILEPSIA

A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects

(2019) Katharina Knaub et al.   MOLECULES

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Elizabeth A Thiele et al.   LANCET

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

(2018) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

(2018) Douglas L. Boggs et al.   PSYCHOPHARMACOLOGY

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

(2018) Lesley Taylor et al.   CNS DRUGS

Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test

(2018) Ila M. Linares et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans

(2018) Sophie A. Millar et al.   Frontiers in Pharmacology

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life

(2017) Antonio W. Zuardi et al.   Frontiers in Pharmacology

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study

(2016) Khalid A. Jadoon et al.   DIABETES CARE

Comparing treatment effects of oral THC on simulated and on-the-road driving performance: testing the validity of driving simulator drug research

(2015) J. L. Veldstra et al.   PSYCHOPHARMACOLOGY

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial

(2014) Marcos Hortes N Chagas et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Exercise increases plasma THC concentrations in regular cannabis users

(2013) Alexander Wong et al.   DRUG AND ALCOHOL DEPENDENCE

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

Effects of Benzodiazepines, Antidepressants and Opioids on Driving

(2011) Tharaka Dassanayake et al.   DRUG SAFETY

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

(2011) Mateus M Bergamaschi et al.   NEUROPSYCHOPHARMACOLOGY

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report

(2010) José Alexandre S Crippa et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Cannabidiol for the treatment of psychosis in Parkinson’s disease

(2008) AW Zuardi et al.   JOURNAL OF PSYCHOPHARMACOLOGY